JP2018506553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506553A5 JP2018506553A5 JP2017544866A JP2017544866A JP2018506553A5 JP 2018506553 A5 JP2018506553 A5 JP 2018506553A5 JP 2017544866 A JP2017544866 A JP 2017544866A JP 2017544866 A JP2017544866 A JP 2017544866A JP 2018506553 A5 JP2018506553 A5 JP 2018506553A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- pyrazol
- methyl
- trifluoromethyl
- symptom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024891 symptom Diseases 0.000 claims 17
- 230000001965 increasing effect Effects 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 7
- 230000007709 intracellular calcium signaling Effects 0.000 claims 7
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 208000004998 Abdominal Pain Diseases 0.000 claims 3
- 239000004382 Amylase Substances 0.000 claims 3
- 102000013142 Amylases Human genes 0.000 claims 3
- 108010065511 Amylases Proteins 0.000 claims 3
- 108091006146 Channels Proteins 0.000 claims 3
- 206010033645 Pancreatitis Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 235000019418 amylase Nutrition 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 3
- 230000008673 vomiting Effects 0.000 claims 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- -1 3-fluoro-4- (3-methyl-1- (thiazol-2-yl) -1H-pyrazol-4-yl) phenyl Chemical group 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims 2
- 102000004882 Lipase Human genes 0.000 claims 2
- 108090001060 Lipase Proteins 0.000 claims 2
- 239000004367 Lipase Substances 0.000 claims 2
- 206010028813 Nausea Diseases 0.000 claims 2
- 102000016387 Pancreatic elastase Human genes 0.000 claims 2
- 108010067372 Pancreatic elastase Proteins 0.000 claims 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims 2
- 206010033799 Paralysis Diseases 0.000 claims 2
- 206010037660 Pyrexia Diseases 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 201000003229 acute pancreatitis Diseases 0.000 claims 2
- 229940125400 channel inhibitor Drugs 0.000 claims 2
- 238000002591 computed tomography Methods 0.000 claims 2
- 102000038379 digestive enzymes Human genes 0.000 claims 2
- 108091007734 digestive enzymes Proteins 0.000 claims 2
- 230000002550 fecal effect Effects 0.000 claims 2
- 235000019421 lipase Nutrition 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000008693 nausea Effects 0.000 claims 2
- 230000004580 weight loss Effects 0.000 claims 2
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 claims 1
- IXXQSGKWJXZNNW-UHFFFAOYSA-N 2-ethyl-6-methyl-1,3-benzoxazole Chemical compound C1=C(C)C=C2OC(CC)=NC2=C1 IXXQSGKWJXZNNW-UHFFFAOYSA-N 0.000 claims 1
- XMLZQZRMVASCQD-UHFFFAOYSA-N 3-fluoro-N-[(3-methyl-1,2-thiazol-4-yl)methyl]-4-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]aniline Chemical compound FC=1C=C(NCC=2C(=NSC=2)C)C=CC=1C1=CC(=NN1C)C(F)(F)F XMLZQZRMVASCQD-UHFFFAOYSA-N 0.000 claims 1
- PHRWOZCIUIIAAJ-UHFFFAOYSA-N 4-chloro-2-methyl-n-[4-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]pyrazole-3-carboxamide Chemical compound CN1N=CC(Cl)=C1C(=O)NC1=CC=C(C=2N(N=C(C=2)C(F)(F)F)C)C=C1 PHRWOZCIUIIAAJ-UHFFFAOYSA-N 0.000 claims 1
- RVMPTRYYRSXIJU-UHFFFAOYSA-N 4-chloro-n-[3-fluoro-4-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]phenyl]-2-methylpyrazole-3-carboxamide Chemical compound CN1N=C(C(F)(F)F)C=C1C(C(=C1)F)=CC=C1NC(=O)C1=C(Cl)C=NN1C RVMPTRYYRSXIJU-UHFFFAOYSA-N 0.000 claims 1
- RLYFWFGERVZBGJ-UHFFFAOYSA-N 5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]-n-[(2,4,6-trifluorophenyl)methyl]pyridin-2-amine Chemical compound CN1N=C(C(F)(F)F)C=C1C(C=N1)=CC=C1NCC1=C(F)C=C(F)C=C1F RLYFWFGERVZBGJ-UHFFFAOYSA-N 0.000 claims 1
- 206010000087 Abdominal pain upper Diseases 0.000 claims 1
- 206010000097 Abdominal tenderness Diseases 0.000 claims 1
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 claims 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 102000020167 Calcium release-activated calcium channel Human genes 0.000 claims 1
- 108091022898 Calcium release-activated calcium channel Proteins 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- 208000005156 Dehydration Diseases 0.000 claims 1
- 102100025027 E3 ubiquitin-protein ligase TRIM69 Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101000830203 Homo sapiens E3 ubiquitin-protein ligase TRIM69 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023126 Jaundice Diseases 0.000 claims 1
- 206010025476 Malabsorption Diseases 0.000 claims 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims 1
- SNZQCHZQWXZHAK-UHFFFAOYSA-N N-[4-[2-ethyl-5-(1,3-thiazol-2-yl)pyrazol-3-yl]phenyl]-2-fluorobenzamide Chemical compound C(C)N1N=C(C=C1C1=CC=C(C=C1)NC(C1=C(C=CC=C1)F)=O)C=1SC=CN=1 SNZQCHZQWXZHAK-UHFFFAOYSA-N 0.000 claims 1
- ZCTBONDBMNFYBP-UHFFFAOYSA-N N-[4-[3-(difluoromethyl)-5-methylpyrazol-1-yl]-3-fluorophenyl]-2,4,6-trifluorobenzamide Chemical compound FC(C1=NN(C(=C1)C)C1=C(C=C(C=C1)NC(C1=C(C=C(C=C1F)F)F)=O)F)F ZCTBONDBMNFYBP-UHFFFAOYSA-N 0.000 claims 1
- WSDSZTWUDQYETA-UHFFFAOYSA-N N-[4-[3-(difluoromethyl)-5-methylpyrazol-1-yl]-3-fluorophenyl]-2,6-difluorobenzamide Chemical compound FC(C1=NN(C(=C1)C)C1=C(C=C(C=C1)NC(C1=C(C=CC=C1F)F)=O)F)F WSDSZTWUDQYETA-UHFFFAOYSA-N 0.000 claims 1
- CMSKRFIQWUMNNG-UHFFFAOYSA-N N-[4-[5-(difluoromethyl)-2-methylpyrazol-3-yl]-3-fluorophenyl]-2,4,6-trifluorobenzamide Chemical compound FC(C1=NN(C(=C1)C1=C(C=C(C=C1)NC(C1=C(C=C(C=C1F)F)F)=O)F)C)F CMSKRFIQWUMNNG-UHFFFAOYSA-N 0.000 claims 1
- HUFILSCTMOFTQE-UHFFFAOYSA-N N-[5-(6-ethoxy-4-methylpyridin-3-yl)-1,3-thiazol-2-yl]-2,3,6-trifluorobenzamide Chemical compound C(C)OC1=CC(=C(C=N1)C1=CN=C(S1)NC(C1=C(C(=CC=C1F)F)F)=O)C HUFILSCTMOFTQE-UHFFFAOYSA-N 0.000 claims 1
- BMFPMPZMORWOGR-UHFFFAOYSA-N N-[5-(6-ethoxy-4-methylpyridin-3-yl)pyrazin-2-yl]-2,6-difluorobenzamide Chemical group C(C)OC1=CC(=C(C=N1)C=1N=CC(=NC=1)NC(C1=C(C=CC=C1F)F)=O)C BMFPMPZMORWOGR-UHFFFAOYSA-N 0.000 claims 1
- IJEDCFPQHNFQGD-UHFFFAOYSA-N N-[5-[2-ethyl-5-(trifluoromethyl)pyrazol-3-yl]pyrazin-2-yl]-2,4,6-trifluorobenzamide Chemical compound CCn1nc(cc1-c1cnc(NC(=O)c2c(F)cc(F)cc2F)cn1)C(F)(F)F IJEDCFPQHNFQGD-UHFFFAOYSA-N 0.000 claims 1
- KZELIELHLIGIBL-UHFFFAOYSA-N N-[5-[2-ethyl-5-(trifluoromethyl)pyrazol-3-yl]pyridin-2-yl]-2,3,6-trifluorobenzamide Chemical compound C(C)N1N=C(C=C1C=1C=CC(=NC=1)NC(C1=C(C(=CC=C1F)F)F)=O)C(F)(F)F KZELIELHLIGIBL-UHFFFAOYSA-N 0.000 claims 1
- 102000049666 ORAI1 Human genes 0.000 claims 1
- 108700027851 ORAI1 Proteins 0.000 claims 1
- 102000049665 ORAI2 Human genes 0.000 claims 1
- 108700027852 ORAI2 Proteins 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010055024 Pancreatic enlargement Diseases 0.000 claims 1
- 206010058096 Pancreatic necrosis Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 102000004094 Stromal Interaction Molecule 1 Human genes 0.000 claims 1
- 108090000532 Stromal Interaction Molecule 1 Proteins 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 102000004142 Trypsin Human genes 0.000 claims 1
- 108090000631 Trypsin Proteins 0.000 claims 1
- 102000018690 Trypsinogen Human genes 0.000 claims 1
- 108010027252 Trypsinogen Proteins 0.000 claims 1
- 230000000740 bleeding effect Effects 0.000 claims 1
- 230000002308 calcification Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 230000037213 diet Effects 0.000 claims 1
- 235000005911 diet Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 208000011316 hemodynamic instability Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 235000019626 lipase activity Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- KWACVWMEBIIKTL-UHFFFAOYSA-N n-[5-(5-chloro-2-methyl-1,3-benzoxazol-6-yl)pyrazin-2-yl]-2,6-difluorobenzamide Chemical compound C1=C2OC(C)=NC2=CC(Cl)=C1C(N=C1)=CN=C1NC(=O)C1=C(F)C=CC=C1F KWACVWMEBIIKTL-UHFFFAOYSA-N 0.000 claims 1
- CGYLBBYAVWRZBJ-UHFFFAOYSA-N n-[5-(7-chloro-2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-6-yl)pyridin-2-yl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2C(=CC=3OCCOC=3N=2)Cl)C=N1 CGYLBBYAVWRZBJ-UHFFFAOYSA-N 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 1
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 1
- 230000011514 reflex Effects 0.000 claims 1
- 230000036387 respiratory rate Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 239000012588 trypsin Substances 0.000 claims 1
- 208000016261 weight loss Diseases 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021138203A JP2021193097A (ja) | 2015-02-27 | 2021-08-26 | 膵炎処置 |
| JP2023091769A JP2023116577A (ja) | 2015-02-27 | 2023-06-02 | 膵炎処置 |
| JP2024165510A JP7783371B2 (ja) | 2015-02-27 | 2024-09-24 | 膵炎処置 |
| JP2025204455A JP2026053342A (ja) | 2015-02-27 | 2025-11-26 | 膵炎処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562126386P | 2015-02-27 | 2015-02-27 | |
| US62/126,386 | 2015-02-27 | ||
| PCT/US2016/019924 WO2016138472A1 (en) | 2015-02-27 | 2016-02-26 | Pancreatitis treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021138203A Division JP2021193097A (ja) | 2015-02-27 | 2021-08-26 | 膵炎処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506553A JP2018506553A (ja) | 2018-03-08 |
| JP2018506553A5 true JP2018506553A5 (https=) | 2019-04-04 |
| JP6985146B2 JP6985146B2 (ja) | 2021-12-22 |
Family
ID=56789809
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017544866A Active JP6985146B2 (ja) | 2015-02-27 | 2016-02-26 | 膵炎処置 |
| JP2021138203A Pending JP2021193097A (ja) | 2015-02-27 | 2021-08-26 | 膵炎処置 |
| JP2023091769A Pending JP2023116577A (ja) | 2015-02-27 | 2023-06-02 | 膵炎処置 |
| JP2024165510A Active JP7783371B2 (ja) | 2015-02-27 | 2024-09-24 | 膵炎処置 |
| JP2025204455A Pending JP2026053342A (ja) | 2015-02-27 | 2025-11-26 | 膵炎処置 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021138203A Pending JP2021193097A (ja) | 2015-02-27 | 2021-08-26 | 膵炎処置 |
| JP2023091769A Pending JP2023116577A (ja) | 2015-02-27 | 2023-06-02 | 膵炎処置 |
| JP2024165510A Active JP7783371B2 (ja) | 2015-02-27 | 2024-09-24 | 膵炎処置 |
| JP2025204455A Pending JP2026053342A (ja) | 2015-02-27 | 2025-11-26 | 膵炎処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US11311535B2 (https=) |
| EP (3) | EP3778595B1 (https=) |
| JP (5) | JP6985146B2 (https=) |
| KR (1) | KR102707159B1 (https=) |
| CN (3) | CN107530333B (https=) |
| AR (1) | AR103807A1 (https=) |
| AU (1) | AU2016224993B2 (https=) |
| BR (1) | BR112017018413B1 (https=) |
| DK (1) | DK3778595T3 (https=) |
| EA (2) | EA202091639A3 (https=) |
| ES (3) | ES2959658T3 (https=) |
| HU (1) | HUE056287T2 (https=) |
| IL (1) | IL254116B2 (https=) |
| PL (1) | PL3778595T3 (https=) |
| PT (1) | PT3778595T (https=) |
| TW (2) | TWI835179B (https=) |
| WO (1) | WO2016138472A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN106414429B (zh) * | 2014-06-03 | 2020-01-03 | 爱杜西亚药品有限公司 | 吡唑化合物及其作为t型钙通道阻断剂的用途 |
| EP3778595B1 (en) | 2015-02-27 | 2021-08-25 | Calcimedica, Inc. | Pancreatitis treatment |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| EP3573610A4 (en) * | 2017-01-26 | 2021-01-13 | Calcimedica, Inc. | CRAC CHANNEL INHIBITOR COMPOSITIONS |
| US10961242B2 (en) | 2017-05-17 | 2021-03-30 | Legochem Biosciences, Inc. | Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same |
| KR101798840B1 (ko) | 2017-05-17 | 2017-11-17 | 주식회사 레고켐 바이오사이언스 | 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물 |
| CN110063945B (zh) * | 2019-04-15 | 2021-07-09 | 温州医科大学 | 一种用于急性胰腺炎治疗的胆红素纳米颗粒及其制备方法 |
| CN114072143A (zh) * | 2019-05-06 | 2022-02-18 | 钙医学公司 | Crac通道抑制剂的合成 |
| WO2021057890A1 (zh) * | 2019-09-25 | 2021-04-01 | 南京明德新药研发有限公司 | 作为crac抑制剂的2h-苯并吡喃衍生物 |
| JP2023528537A (ja) * | 2020-03-20 | 2023-07-04 | カルシメディカ，インク． | 急性肺傷害及び急性呼吸窮迫症候群を処置するための方法及び組成物 |
| CN116261468A (zh) * | 2020-05-20 | 2023-06-13 | 钙医学公司 | 治疗急性肾损伤的方法和组合物 |
| US11413270B2 (en) * | 2020-06-22 | 2022-08-16 | Novmetapharma Co., Ltd. | Method for the treatment of pancreatitis |
| US12496309B2 (en) | 2020-06-22 | 2025-12-16 | Novmetapharma Co., Ltd. | Method for treatment of pancreatitis |
| WO2022032238A1 (en) * | 2020-08-07 | 2022-02-10 | Board Of Regents, The University Of Texas System | Methods and compositions for pancreatic cancer evaluation and treatment |
| CA3198798A1 (en) | 2020-11-13 | 2022-05-19 | Kenneth Stauderman | Improved synthesis of crac channel inhibitors |
| WO2022179577A1 (zh) * | 2021-02-25 | 2022-09-01 | 南京明德新药研发有限公司 | 一种环丙基取代的苯并呋喃类化合物的晶型及其制备方法 |
| CN113424795B (zh) * | 2021-05-24 | 2022-09-09 | 四川大学华西医院 | 一种急性胰腺炎动物模型的构建方法和用途 |
| CN113903460A (zh) * | 2021-12-10 | 2022-01-07 | 中国医学科学院北京协和医院 | 一种预测重症急性胰腺炎的系统及其应用 |
| CN118871110A (zh) * | 2022-01-20 | 2024-10-29 | 钙医学公司 | 用于治疗肺部的炎症损伤的方法和组合物 |
| CN114522157B (zh) * | 2022-02-23 | 2023-08-15 | 重庆大学 | 钙离子螯合剂在制备用于提高血管内皮细胞吞噬能力的制剂中的应用 |
| CN120272478B (zh) * | 2025-03-28 | 2025-12-09 | 山西医科大学 | 一种抗寨卡病毒的靶点抑制剂、重组基因、表达载体及应用 |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5424289A (en) | 1977-07-26 | 1979-02-23 | Mitsubishi Chem Ind Ltd | Production of spherical diatomaceous earth carrier |
| WO1998006719A1 (en) | 1996-08-09 | 1998-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | 4-substituted beta-carbolines as immunomodulators |
| AU751139B2 (en) | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| WO1999051580A1 (en) | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
| WO1999062885A1 (en) | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
| PL205059B1 (pl) | 1999-08-20 | 2010-03-31 | Dow Agrosciences Llc | Heterocykliczny amid aromatyczny, jego kompozycja grzybobójcza oraz sposób zwalczania lub zapobiegania zakażeniom grzybami |
| JP3910319B2 (ja) | 1999-09-13 | 2007-04-25 | 株式会社小糸製作所 | 自動車用灯具 |
| EP1143013A1 (en) | 2000-04-03 | 2001-10-10 | Warner-Lambert Company | Methods and compositions for screening Icrac modulators |
| WO2002096416A1 (en) | 2001-05-31 | 2002-12-05 | Cellegy Pharmaceuticals, Inc. | Store operated calcium influx inhibitors and methods of use |
| GB0225554D0 (en) | 2002-11-01 | 2002-12-11 | Syngenta Participations Ag | Chemical compounds |
| US8030336B2 (en) | 2002-12-13 | 2011-10-04 | Ym Biosciences Australia Pty Ltd | Nicotinamide-based kinase inhibitors |
| WO2004056774A2 (en) | 2002-12-19 | 2004-07-08 | Neurogen Corporation | Substituted biphenyl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators |
| US7645588B2 (en) | 2003-03-04 | 2010-01-12 | Calcimedica, Inc. | Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use |
| TWI376370B (en) | 2003-07-23 | 2012-11-11 | Synta Pharmaceuticals Corp | Compounds for inflammation and immune-related uses |
| DE102004005785A1 (de) | 2004-02-06 | 2005-08-25 | Bayer Cropscience Ag | 2-Halogenfuryl/thienyl-3-carboxamide |
| WO2006006569A1 (ja) | 2004-07-12 | 2006-01-19 | Nihon Nohyaku Co., Ltd. | フェニルピリジン類又はその塩類、これらを有効成分とする除草剤及びその使用方法 |
| KR20070057965A (ko) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| US8557861B2 (en) | 2004-09-28 | 2013-10-15 | Mast Therapeutics, Inc. | Low oil emulsion compositions for delivering taxoids and other insoluble drugs |
| KR20140018997A (ko) | 2005-01-07 | 2014-02-13 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| EP1846388A4 (en) | 2005-01-25 | 2011-12-07 | Synta Pharmaceuticals Corp | THIOPHEN COMPOUNDS FOR IGNITIONS AND THE IMMUNE SYSTEM APPLICATIONS |
| PL1848435T3 (pl) | 2005-01-25 | 2016-08-31 | Synta Pharmaceuticals Corp | Związki przeciwko zapaleniom i zastosowania związane z odpornością |
| MX2007009888A (es) | 2005-02-17 | 2007-10-16 | Synta Pharmaceuticals Corp | Compuestos para el tratamiento de trastornos proliferativos. |
| US20060235028A1 (en) | 2005-04-14 | 2006-10-19 | Li James J | Inhibitors of 11-beta hydroxysteroid dehydrogenase type I |
| WO2007035874A1 (en) | 2005-09-21 | 2007-03-29 | Bristol-Myers Squibb Company | Oral administration of n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-1,3-thiazole-5-carboxamide and salts thereof |
| NL2000284C2 (nl) | 2005-11-04 | 2007-09-28 | Pfizer Ltd | Pyrazine-derivaten. |
| EP1945632B1 (en) | 2005-11-08 | 2013-09-18 | Vertex Pharmaceuticals Incorporated | Heterocyclic modulators of atp-binding cassette transporters |
| US20070134341A1 (en) | 2005-11-15 | 2007-06-14 | Kipp James E | Compositions of lipoxygenase inhibitors |
| JP5881270B2 (ja) | 2006-01-05 | 2016-03-09 | チルドレンズ メディカル センター コーポレーション | Ｎｆａｔの制御因子 |
| US8455658B2 (en) | 2006-01-25 | 2013-06-04 | Synta Pharmaceuticals Corp. | Thiazole and thiadiazole compounds for inflammation and immune-related uses |
| TW200806641A (en) | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted aromatic compounds for inflammation and immune-related uses |
| TW200806290A (en) | 2006-01-25 | 2008-02-01 | Synta Pharmaceuticals Corp | Substituted biaryl compounds for inflammation and immune-related uses |
| WO2007087429A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| US7816535B2 (en) | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
| US20070254926A1 (en) | 2006-01-31 | 2007-11-01 | Jun Jiang | Pyridylphenyl compounds for inflammation and immune-related uses |
| US7951824B2 (en) | 2006-02-17 | 2011-05-31 | Hoffman-La Roche Inc. | 4-aryl-pyridine-2-carboxyamide derivatives |
| AU2007227210A1 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| WO2007120600A2 (en) | 2006-04-10 | 2007-10-25 | Arena Pharmaceuticals, Inc. | 3-pyridinyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| PL3357911T3 (pl) | 2006-06-26 | 2022-09-05 | Akebia Therapeutics Inc. | Inhibitory prolilohydroksylazy i sposoby ich użycia |
| US20080207641A1 (en) | 2006-11-13 | 2008-08-28 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
| JP2010519206A (ja) | 2007-02-16 | 2010-06-03 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連使用のための置換縮合環化合物 |
| CA2688417C (en) | 2007-05-24 | 2017-04-25 | Calcimedica, Inc. | Calcium channel proteins and uses thereof |
| CA2695143A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Heterocycle-aryl compounds for inflammation and immune-related uses |
| WO2009017831A1 (en) | 2007-08-01 | 2009-02-05 | Synta Pharmaceuticals Corp. | Vinyl-aryl derivatives for inflammation and immune-related uses |
| CA2695621A1 (en) | 2007-08-09 | 2009-02-12 | Merck Sharp & Dohme Corp. | Pyridine carboxamide orexin receptor antagonists |
| US8263641B2 (en) | 2007-09-10 | 2012-09-11 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20110052643A1 (en) | 2008-01-07 | 2011-03-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
| JP2011513332A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体 |
| US20110305709A1 (en) | 2008-03-20 | 2011-12-15 | Attila Braun | Calcium sensor stim1 and the platelet soc channel orai1 (cracm1) are essential for pathological thrombus formation |
| US20100016598A1 (en) | 2008-07-16 | 2010-01-21 | Wyeth | Alpha7 nicotinic acetylcholine receptor inhibitors |
| TWI392673B (zh) | 2008-08-27 | 2013-04-11 | Calcimedica Inc | 調控細胞內鈣離子濃度之化合物 |
| US20110269743A1 (en) | 2008-09-22 | 2011-11-03 | CalciMedica, Inc | Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release |
| US8524763B2 (en) | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| AU2009300317A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| AU2009300318A1 (en) | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| WO2010048559A2 (en) | 2008-10-24 | 2010-04-29 | Calcimedica Inc. | Phenylpyrazole inhibitors of store operated calcium release |
| AR076373A1 (es) | 2009-04-24 | 2011-06-08 | Glaxo Group Ltd | N-pirazolil carboxamidas como inhibidores de canales de calcio |
| EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
| EP3167875A1 (en) | 2009-05-27 | 2017-05-17 | Alkermes Pharma Ireland Limited | Reduction of flake-like aggregation in nanoparticulate meloxicam compositions |
| EP2477982A4 (en) | 2009-09-16 | 2013-04-03 | Calcimedica Inc | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
| US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US20120231006A1 (en) | 2009-11-20 | 2012-09-13 | Amgen Inc. | Anti-orai1 antigen binding proteins and uses thereof |
| US8476006B2 (en) * | 2009-11-30 | 2013-07-02 | National Center For Biological Sciences | Store-operated calcium cellular assay |
| JP5748777B2 (ja) | 2010-02-02 | 2015-07-15 | ノバルティス アーゲー | Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体 |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2563759B1 (en) | 2010-04-27 | 2022-04-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP6112486B2 (ja) | 2010-04-27 | 2017-04-12 | カルシメディカ，インク． | 細胞内カルシウムを調節する化合物 |
| EP2609095A4 (en) * | 2010-08-27 | 2014-06-18 | Calcimedica Inc | COMPOUNDS MODULATING INTRACELLULAR CALCIUM |
| CA2834928C (en) | 2011-05-03 | 2017-10-17 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US20130143927A1 (en) | 2011-06-10 | 2013-06-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US20120316182A1 (en) * | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059666A1 (en) * | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| JP5936350B2 (ja) | 2011-12-27 | 2016-06-22 | キヤノン株式会社 | 新規有機化合物 |
| CA2871270A1 (en) * | 2012-05-02 | 2013-11-07 | Lupin Limited | Substituted pyridine compounds as crac modulators |
| WO2014043715A1 (en) | 2012-09-17 | 2014-03-20 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2014203217A1 (en) | 2013-06-21 | 2014-12-24 | Lupin Limited | Substituted heterocyclic compounds as crac modulators |
| EP3778595B1 (en) * | 2015-02-27 | 2021-08-25 | Calcimedica, Inc. | Pancreatitis treatment |
| CA2995094A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
| EP3573610A4 (en) | 2017-01-26 | 2021-01-13 | Calcimedica, Inc. | CRAC CHANNEL INHIBITOR COMPOSITIONS |
| CA3115230A1 (en) | 2018-10-04 | 2020-04-09 | The Trustees Of Indiana University | Methods to treat renal disorders using calcium channel inhibitors |
| JP2023528537A (ja) | 2020-03-20 | 2023-07-04 | カルシメディカ，インク． | 急性肺傷害及び急性呼吸窮迫症候群を処置するための方法及び組成物 |
| CN116261468A (zh) | 2020-05-20 | 2023-06-13 | 钙医学公司 | 治疗急性肾损伤的方法和组合物 |
-
2016
- 2016-02-26 EP EP20200080.8A patent/EP3778595B1/en active Active
- 2016-02-26 AU AU2016224993A patent/AU2016224993B2/en active Active
- 2016-02-26 TW TW111123836A patent/TWI835179B/zh active
- 2016-02-26 PT PT202000808T patent/PT3778595T/pt unknown
- 2016-02-26 HU HUE20200080A patent/HUE056287T2/hu unknown
- 2016-02-26 DK DK20200080.8T patent/DK3778595T3/da active
- 2016-02-26 CN CN201680024735.5A patent/CN107530333B/zh active Active
- 2016-02-26 EP EP16756509.2A patent/EP3261641B1/en active Active
- 2016-02-26 KR KR1020177026940A patent/KR102707159B1/ko active Active
- 2016-02-26 TW TW105106002A patent/TWI771269B/zh active
- 2016-02-26 BR BR112017018413-3A patent/BR112017018413B1/pt active IP Right Grant
- 2016-02-26 EP EP23184730.2A patent/EP4275705B1/en active Active
- 2016-02-26 ES ES16756509T patent/ES2959658T3/es active Active
- 2016-02-26 EA EA202091639A patent/EA202091639A3/ru unknown
- 2016-02-26 ES ES20200080T patent/ES2899197T3/es active Active
- 2016-02-26 CN CN202010670349.1A patent/CN111773391A/zh active Pending
- 2016-02-26 ES ES23184730T patent/ES3033759T3/es active Active
- 2016-02-26 JP JP2017544866A patent/JP6985146B2/ja active Active
- 2016-02-26 US US15/553,531 patent/US11311535B2/en active Active
- 2016-02-26 CN CN202210191615.1A patent/CN114712513B/zh active Active
- 2016-02-26 EA EA201791811A patent/EA036265B1/ru unknown
- 2016-02-26 WO PCT/US2016/019924 patent/WO2016138472A1/en not_active Ceased
- 2016-02-26 PL PL20200080T patent/PL3778595T3/pl unknown
- 2016-02-26 AR ARP160100518A patent/AR103807A1/es not_active Application Discontinuation
-
2017
- 2017-08-23 IL IL254116A patent/IL254116B2/en unknown
-
2020
- 2020-08-07 US US16/988,508 patent/US10821109B1/en active Active
- 2020-10-22 US US17/077,818 patent/US11013737B2/en active Active
-
2021
- 2021-03-16 US US17/203,547 patent/US11752148B2/en active Active
- 2021-08-26 JP JP2021138203A patent/JP2021193097A/ja active Pending
- 2021-09-10 US US17/472,422 patent/US11439639B2/en active Active
-
2023
- 2023-06-02 JP JP2023091769A patent/JP2023116577A/ja active Pending
-
2024
- 2024-03-01 US US18/593,518 patent/US20240307384A1/en active Pending
- 2024-09-24 JP JP2024165510A patent/JP7783371B2/ja active Active
-
2025
- 2025-11-26 JP JP2025204455A patent/JP2026053342A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506553A5 (https=) | ||
| JP7783371B2 (ja) | 膵炎処置 | |
| US20130030007A1 (en) | Obesity Small Molecules | |
| JP2010507096A (ja) | 有機化合物 | |
| US20230226058A1 (en) | Methods and compositions for treating acute kidney injury | |
| RU2768943C1 (ru) | Фармацевтическая композиция для предупреждения или лечения неалкогольной жировой инфильтрации печени, содержащая лиганд gpr119 в качестве активного ингредиента | |
| JP2015510947A5 (https=) | ||
| JP7469499B2 (ja) | 非アルコール性脂肪性肝炎の予防または治療用の薬学的組成物 | |
| WO2026096796A1 (en) | Methods for treating acute pancreatitis | |
| JPH08175991A (ja) | アレルギー性皮膚炎の処置剤 | |
| EA042387B1 (ru) | Лечение панкреатита | |
| HK1244686B (zh) | 胰腺炎治疗 |